Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria

BACKGROUND/AIMS: Ustekinumab is effective in active Crohn’s disease. In a retrospective study, we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin inhibitor vedolizumab. As approval study populations do not alw...

Descripción completa

Detalles Bibliográficos
Autores principales: Saman, Sadik, Goetz, Martin, Wendler, Judith, Malek, Nisar P., Wehkamp, Jan, Klag, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667371/
https://www.ncbi.nlm.nih.gov/pubmed/31129948
http://dx.doi.org/10.5217/ir.2019.00012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667371/
https://www.ncbi.nlm.nih.gov/pubmed/31129948
http://dx.doi.org/10.5217/ir.2019.00012

Ejemplares similares